Scarica l'app Stockscreener
12.63
1.10%
-0.14
Dopo l'orario di chiusura:
12.63
Precedente Chiudi:
$12.77
Aprire:
$12.95
Volume 24 ore:
1.60M
Relative Volume:
1.19
Capitalizzazione di mercato:
$1.10B
Reddito:
-
Utile/perdita netta:
$-185.15M
Rapporto P/E:
-6.2361
EPS:
-2.0253
Flusso di cassa netto:
$-148.72M
1 W Prestazione:
+0.96%
1M Prestazione:
+22.50%
6M Prestazione:
-53.34%
1 anno Prestazione:
+183.82%
Intervallo 1D:
$12.39
$13.09
Intervallo di 1 settimana:
$11.81
$13.09
Portata 52W:
$4.37
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Nome
Olema Pharmaceuticals Inc
Settore
Industria
Telefono
(415) 651-3316
Indirizzo
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
12.63 | 1.12B | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Peer Perform |
| 2026-03-19 | Ripresa | Jefferies | Buy |
| 2026-02-11 | Iniziato | Stifel | Buy |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-12 | Reiterato | Citigroup | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2024-01-30 | Iniziato | Citigroup | Buy |
| 2023-07-21 | Iniziato | Oppenheimer | Outperform |
| 2023-05-05 | Iniziato | CapitalOne | Overweight |
| 2023-02-22 | Iniziato | Credit Suisse | Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Iniziato | H.C. Wainwright | Neutral |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2020-12-14 | Iniziato | Canaccord Genuity | Buy |
| 2020-12-14 | Iniziato | Cowen | Outperform |
| 2020-12-14 | Iniziato | JP Morgan | Overweight |
| 2020-12-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Olema Pharmaceuticals Inc Borsa (OLMA) Ultime notizie
Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Oncology awards 215,800 options to eight new employees - Stock Titan
Olema Pharmaceuticals (OLMA) Is Up 22.0% After Broad Russell Growth Index InclusionHas The Bull Case Changed? - simplywall.st
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story? - Yahoo Finance
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2500 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2000 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell 3000E Growth Benchmark - marketscreener.com
Olema Pharmaceuticals (OLMA) Holds Steady Near Support Amid Minor DeclineUp Down Volume - dars.gov.et
Olema Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:OLMA) - TradingView
OLMA Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Australia
Olema (NASDAQ: OLMA) awards director 29,500 stock options - Stock Titan
BVF group (NASDAQ: OLMA) reports 29,500 new options and large pre-funded warrants - Stock Titan
Olema (NASDAQ: OLMA) director receives grant of 29,500 stock options at $9.51 - Stock Titan
Olema Pharmaceuticals (OLMA) director awarded 29,500 stock options at $9.51 strike price - Stock Titan
Olema (OLMA) director Garland J. Scott awarded 29,500 stock options at $9.51 - Stock Titan
[Form 4] Olema Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Olema Pharmaceuticals (OLMA) director granted 29,500 stock options at $9.51 strike - Stock Titan
Olema (OLMA) director receives 29,500 options at $9.51 strike price - Stock Titan
Olema (OLMA) director granted 29,500 stock options at $9.51 exercise price - Stock Titan
Olema (NASDAQ: OLMA) director granted 29,500 stock options at $9.51 strike price - Stock Titan
Olema (OLMA) director Graham Walmsley awarded 29,500 stock options at $9.51 - Stock Titan
Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young - Stock Titan
What Prompted the Chief Legal Officer's Recent OLMA Share Sales - Kavout
Olema Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Olema Pharmaceuticals Inc (OLMA) Institutional Confidence - TradingKey
Olema Pharmaceuticals Inc (OLMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Olema Pharmaceuticals Inc (OLMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Olema Pharmaceuticals Inc (OLMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Olema Pharmaceuticals Inc (OLMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Olema Pharmaceuticals Inc (OLMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet - Insider Monkey
10 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
OLMA Stock Soars 47% in September So Far on Second PFE Deal - MSN
OLMA,GH Options - Finviz
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Olema Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
InvestingPro’s Fair Value flagged Olema stock as overvalued at $19.49 By Investing.com - Investing.com Canada
OLMA Q1 2026 Earnings: Narrower-Than-Expected Loss as Biotech Advances PipelineNegative Surprise Momentum - newsline.com
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
UBS Remains a Buy on Olema Pharmaceuticals (OLMA) - The Globe and Mail
OLMA Technical Analysis | Trend, Signals & Chart Patterns | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
A Look At Olema Pharmaceuticals (OLMA) Valuation After New Bayer Collaboration And OP-3136 Phase 1 Data - Sahm
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $24 - Moomoo
Guggenheim Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $35 - Moomoo
Olema Pharmaceuticals Inc Azioni (OLMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):